These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 17542746

  • 1. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
    Flowers CR.
    Expert Rev Vaccines; 2007 Jun; 6(3):307-17. PubMed ID: 17542746
    [Abstract] [Full Text] [Related]

  • 2. Translational development of vaccination strategies in follicular NHL.
    Sakamaki I, Qin H, Kwak LW.
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW.
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Idiotype vaccine strategies for treatment of follicular lymphoma.
    Mahaseth H, Brody JD, Sinha R, Shenoy PJ, Flowers CR.
    Future Oncol; 2011 Jan; 7(1):111-22. PubMed ID: 21174542
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R.
    Cancer Res; 2002 Oct 15; 62(20):5845-52. PubMed ID: 12384547
    [Abstract] [Full Text] [Related]

  • 8. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.
    Lee ST, Jiang YF, Park KU, Woo AF, Neelapu SS.
    Expert Opin Biol Ther; 2007 Jan 15; 7(1):113-22. PubMed ID: 17150023
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase III randomized study of autologous lymphoma-derived idiotype specific vaccination plus GM-CSF in patients with follicular lymphoma in first complete remission.
    Clin Adv Hematol Oncol; 2003 Jan 15; 1(1):67. PubMed ID: 16227966
    [No Abstract] [Full Text] [Related]

  • 11. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
    Yáñez R, Barrios Y, Ruiz E, Cabrera R, Díaz-Espada F.
    J Immunother; 2008 Apr 15; 31(3):310-2. PubMed ID: 18317357
    [Abstract] [Full Text] [Related]

  • 12. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
    Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL, Kwak LW.
    Nat Med; 1999 Oct 15; 5(10):1171-7. PubMed ID: 10502821
    [Abstract] [Full Text] [Related]

  • 13. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
    Gadri Z, Kukulansky T, Bar-Or E, Haimovich J, Hollander N.
    J Immunother; 2009 May 15; 32(4):333-40. PubMed ID: 19342972
    [Abstract] [Full Text] [Related]

  • 14. Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma.
    Reinis M.
    Curr Opin Mol Ther; 2007 Jun 15; 9(3):291-8. PubMed ID: 17608028
    [Abstract] [Full Text] [Related]

  • 15. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
    Inogès S, Rodrìguez-Calvillo M, Zabalegui N, Lòpez-Dìaz de Cerio A, Villanueva H, Soria E, Suárez L, Rodríguez-Caballero A, Pastor F, García-Muñóz R, Panizo C, Pèrez-Calvo J, Melero I, Rocha E, Orfao A, Bendandi M, Grupo Español de Linfomas/Trasplante Autologo de Medula Oseo study group, Programa para el Estudio y Tratamiento de Hemopatias Malignas study group.
    J Natl Cancer Inst; 2006 Sep 20; 98(18):1292-301. PubMed ID: 16985248
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
    Freedman A, Neelapu SS, Nichols C, Robertson MJ, Djulbegovic B, Winter JN, Bender JF, Gold DP, Ghalie RG, Stewart ME, Esquibel V, Hamlin P.
    J Clin Oncol; 2009 Jun 20; 27(18):3036-43. PubMed ID: 19414675
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
    Hurvitz SA, Timmerman JM.
    Expert Opin Biol Ther; 2005 Jun 20; 5(6):841-52. PubMed ID: 15952914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.